tumor antigens

(redirected from tumour antigens)

tu·mor an·ti·gens

1. antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific);
2. tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses.
Synonym(s): neoantigens (2)

See also: T antigens.

tu·mor an·ti·gens

(tū'mŏr an'ti-jenz)
1. Those antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific).
2. Tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses.
See also: T antigens
Synonym(s): neoantigens, tumour antigens.
References in periodicals archive ?
Reportedly, CV301 is specifically designed to elicit T-cells against the tumour antigens CEA and MUC1, both of which are highly overexpressed in colorectal cancers.
Tumour antigens, unique proteins on the surface of a tumour, are potential targets for a normal immune response against cancer.
In addition to increasing transport of tumour antigens and regulatory cytokines to the lymph node, increased lymph flow in the tumour margin causes mechanical stress-induced changes in stromal cells that stiffen the matrix and alter the immune microenvironment of the tumour.
Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them.
While chronic inflammation that is often associated with the recruitment of innate immune cells to tumours promotes cancer, acute inflammatory responses can counteract immunosuppressive mechanisms operating in many tumours and allow tumour infiltration by lymphocytes to induce adaptive immune responses against tumour antigens.
The therapeutic platform combines a completely novel proprietary and IP-protected approach - the utilisation of a bacterial danger signal in combination with the patient's tumour antigens - with a proven successful concept (dendritic cells) to mobilise the patients' immune system to combat the disease.
CV301 is designed to generate a T cell response to both CEA and MUC1, two tumour antigens that are highly over expressed in bladder cancers.
An ImmunoBody[R] is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells.
IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response, added the company.
Unlike traditional CAR-T cell therapy, which target only one tumour antigen, Natural Killer (NK) cell receptors enable a single receptor to recognise multiple tumour antigens.
An ImmunoBody[R] is a DNA vaccine encoding a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells.